PO.ET01.04 · 实验与分子治疗
Kinase and Signaling Pathway Dependencies Driving Cancer Therapeutic Response
-
- 317 317 Glucose conditions influence CAMKK2-targeted therapy sensitivity in triple-negative breast cancer of different ancestry Elham Amini, Sree latha Aramgam, Kenisha Webb, Sean Kimbro
-
- 319 319 An analysis of orthosteric missense kinase mutations among a clinical sequencing cohort of over 90,000 cancer patients Jessica B. White, John D. Chodera, Wesley Tansey
- 320 320 Targeting overexpressed TTK and NEK2 decreases early metastatic potential of triple-negative breast cancer cell lines Alexandra N. Aquino-Acevedo, Ángel D. Colón-Burgos, Esther M. Irizarry-Quintana, Elliott Rodriguez-Lopez, Joel A. Orengo-Orengo, Marileana Rodriguez-Ruiz, Gretchen M. Albarrán-Acosta, Melanie E. Cruz-Robles, Harold I. Saavedra
-
- 322 322 Differential effects of SRPK1 inhibition on HPV⁺ and HPV⁻ in cervical cancer: Transcriptome and splicing rewiring Afra Tsitsi Basera, Mohammed Alaouna, Janie Duvanhage, David Bates, Zodwa Dlamini, Rahaba Marima
- 323 323 Dual inhibition of SIK2/3 induces ER Stress and ER-phagy, enhancing the cytotoxicity of autophagy blockade in ovarian cancer Rumeysa Ozyurt, Gamze Bildik Elcik, Weiqun Mao, Robert C. Bast, Zhen Lu
-
- 325 325 Development of the pyridopyrimidine derivative KC12 as a selective dual Pim/Mnk inhibitor to inhibit leukemia cell growth Linxiang Zhao, Kun Xing, Jingyi Zhang, Shuwei Zuo, Fuyao Zhang, Samuel Waxman, Yongkui Jing
- 326 326 Association of off targets of ALK inhibitors with their adverse reactions revealed by a novel comprehensive phosphorylation profiling platform Katsuhisa Horimoto, Satoshi Mikami, Lili Feng, Yu Zhang, Dongyin Chen, Feng Han, Satoshi Yamasaki, Shota Takei, Hiroshi Kagamu
- 327 327 MARK2/MARK3/MARK4 kinases are therapeutic targets for human head and neck squamous cell carcinoma with co-dependencies of YAP-TEAD pathway Se Eung Oh, Hwan Jung Lim, Seong Jun Park, Sang Uk Han, Jee Hung Kim, Seo Young Lee, Hei-Cheul Jeung
-
- 329 329 PLK1 inhibitor onvansertib potentiates the antitumor efficacy of trastuzumab deruxtecan (T-DXd) and reverses its resistance in therapy-resistant HER2-low breast cancer models Sreeja Sreekumar, Elodie Montaudon, Zeena Eblimit, Migdalia Gonzalez, Davis Klein, Heloise Derrien, Ahmed Dahmani, Tod Smeal, Elisabetta Marangoni, Maya Ridinger
-
- 332 332 AKT1 mediated post translational modification of the glucocorticoid receptor drives resistance to prostate cancer therapy Surendra Gulla, Tej Sharma, Ephraim Gardner, Abbas Jawadala, Sasikumar Ponnusamy, Tobi Ogunbowale, Maddie Aust, Jonathan E. Bard, Remi Adelaiye-Ogala
- 333 333 Downregulation of AURKA and AURKB promotes a decrease in cell invasion in TNBC by modulating the expression of SNAIL1 Joel Alexis Orengo Orengo, Elliott Rodriguez-Lopez, Selimar Álvarez Velázquez, William Frank Rodríguez, Alexandra N. Aquino-Acevedo, Melanie E. Cruz Robles, Harold Ivan Saavedra
- 334 334 A novel inhibitor of the atypical protein kinase C-ι decreases the proliferation of malignant gastric cancer cells and disrupts the Skp-2 pathway Abiral Hasib Shourav, Nuzhat Nowshin Oishee, Abigail Oluwafisayo Olatunji, Mahfuza Marzan, Khandker M. Khalid, Radwan Ebna Noor, Shreejana Rimal, Mildred Acevedo-Duncan
- 335 335 Inhibition study of protein kinase C-iota mediated signaling pathways in diffuse midline glioma by ICA-1S inhibitor and temozolomide Radwan Ebna Noor, Nuzhat Nowshin Oishee, Abir Hasib Shourav, Mahfuza Marzan, Javad Nazarian, Michelle Monje, Mildred Acevedo-Duncan
- 336 336 Modular control of Pancreatic ductal adenocarcinoma (PDAC) progression by the substrate interaction domains of ERK2 Monika Verma, Billy Truong, Sven Miller, Rachael Price, Dietmar Kappes, Paul Shapiro, Igor Astsaturov, David L. Wiest
- 337 337 Off-target activation of GCN2 by BRAF V600 inhibitors attenuates melanoma outgrowth C. Ryland Ill, Nasreen C. Marikar, Vu T. Nguyen, Brianna Fernandez, Varuna Nangia, Alicia M. Darnell, Matthew G. Vander Heiden, Philip Reigan, Sabrina L. Spencer
-
